Sign up
Pharma Capital

ANGLE PLC sees big opportunities in non-invasive prenatal testing

Andrew Newland, chief executive of ANGLE PLC (LON:AGL, OTCQX:ANPCY), tells Proactive London's Andrew Scott its device for detecting the early signs of cancer has shown promise harvesting fetal cells.

Parsortix appeared to score well against existing methods of non-invasive prenatal testing (NIPT).

Specifically, it was able to harvest intact cells, which could then be assessed for abnormalities such Down’s Syndrome.

 

View full AGL profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.